This extensive review centers on engineered Interleukin-3 (IL-3), a significant molecule participating in hematopoiesis and inflammatory activities. It discusses its structure and process of impact, featuring data from preclinical studies and clinical implementations. Furthermore , the article investigates ongoing clinical potential and limitations